Mei Ri Jing Ji Xin Wen·2025-06-24 15:14Core Viewpoint - Fosun Pharma has completed its board of directors' re-election and appointed a new senior management team, indicating a strategic shift towards leveraging internal talent with extensive experience in the company [1][2]. Group 1: Board of Directors and Management Changes - Chen Yuqing has been appointed as the Chairman, with Guan Xiaohui as Co-Chairman and Wen Deyong as Vice Chairman [1]. - The new CEO and President, Liu Yi, will take office on June 24, 2025, alongside Co-Presidents Li Jing, Wang Xingli, and Zhang Wenjie [1]. - The majority of the new board members have long tenures within the company, showcasing a preference for internal candidates [1][2]. Group 2: Background of Key Executives - Chen Yuqing joined Fosun Pharma in January 2010 and has held various HR-related positions before becoming Co-CEO in June 2022 [1]. - Guan Xiaohui has been with the company since May 2000, previously serving as CFO and holding various leadership roles [1][2]. - Wen Deyong, who has a pharmacy background, joined Fosun Pharma in May 2002 and has held significant positions within the company [2]. Group 3: New Executive Team Profiles - Zhang Wenjie, newly appointed Executive President, was previously known for his role at Fosun Pharma's innovative drug platform, Fuhong Hanlin, and has experience in international pharmaceutical companies [3]. - Liu Yi, the current CEO, has been with the company since November 2015 and has a background in medical devices and diagnostics [3]. - Other new executives, such as Li Jing and Wang Xingli, bring solid pharmaceutical backgrounds and experience from major pharmaceutical companies [2].